Dehydroepiandrosterone (DHEA) (Synonyms: Androstenolone, trans-Dehydroandrosterone, DHEA, Diandrone, NSC 9896, Prasterone, Psicosterone) |
Catalog No.GC11070
One-Click Copy Product Info
|
Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEAS, together represent the most abundant steroid hormones in the human body .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53-43-0
Sample solution is provided at 25 µL, 10mM.
Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEAS, together represent the most abundant steroid hormones in the human body [1].
Dehydroepiandrosterone (DHEA) (10-8 and 10-6 M) or DHEAS pretreated rat cerebral cortical cultures was increased neuronal survival when the cultures subjected to anoxia for 2 h [2]. When rat cerebral cortical cultures were subjected to anoxia for 2 h in an anaerobic chamber and pretreated with dehydroepiandrosterone (DHEA) (10-8 and 10-6 M) or DHEAS (10-6 M), there was increased neuronal survival. Using cultured neural precursors from rat embryonic forebrains, dehydroepiandrosterone (DHEA) (50 and 100 nM) activated the serine-threonine protein kinase Akt, which is widely implicated in cell survival signaling [3].
Dehydroepiandrosterone (DHEA) treating had better locomotor recovery on CD-1 female mice, after contusive spinal cord injury (SCI), and also left-right coordination, and fine motor control than control animals [4]. Mice treated with dehydroepiandrosterone (DHEA) also had significantly more white matter spared at the epicenter of the injury and reduced area of reactive gliosis surrounding the lesion. Dehydroepiandrosterone (DHEA) treatment was intensive and consisted of three different modes of administration: a DHEA Matrigel patch (10-10 M) applied to the spinal cord before closure of the wound, followed by 12 days of i.p. injections of saline containing Dehydroepiandrosterone (DHEA) (10-6 M or 0.02 mg/kg/day) after SCI, and Dehydroepiandrosterone (DHEA) (10-6 M) in the drinking water for 42 days [4].
References:
[1]. Rice SP, Zhang L, Grennan-Jones F, Agarwal N, Lewis MD, Rees DA, Ludgate M: Dehydroepiandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Mol Cell Endocrinol 2010, 320: 51-57. 10.1016/j.mce.2010.02.017
[2]. C.E. Marx, L.F. Jarskog, J.M. Lauder, J.H. Gilmore, J.A. Lieberman, A.L. Morrow. Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res., 871 (2000), pp. 104-112
[3]. L. Zhang, B. Li, W. Ma, J.L. Barker, Y.H. Chang, W. Zhao, D.R. Rubinow. Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signaling pathway in opposing ways. Brain Res. Mol. Brain Res., 98 (2002), pp. 58-66
[4]. C. Fiore, D.M. Inman, S. Hirose, L.J. Noble, T. Igarashi, N.A. Compagnone. Treatment with the neurosteroid dehydroepiandrosterone promotes recovery of motor behavior after moderate contusive spinal cord injury in the mouse. J. Neurosci. Res., 75 (2004), pp. 391-400
| Cell experiment [1]: | |
|
Cell lines |
HCC1 cell line |
|
Preparation Method |
Transferred cells to serum-free dehydroepiandrosterone (DHEA) containing either 0.1% ethanol which was added to all control cultures or 10-12-10-6 M DHEA. The cell culture supernatant was harvested after 72 h. |
|
Reaction Conditions |
10-12-10-6 M for 72 hours |
|
Applications |
Co-treatment with DEX (10-7 M)/ANDI (10-7 M) or DEX (10-7 M)/DHEA (10-7 M) reversed the increase in RANKL mRNA expression |
| Animal experiment [2]: | |
|
Animal models |
female BALB/c mice |
|
Preparation Method |
Effects of treatment with dehydroepiandrosterone (DHEA) were assessed on either ovaries with functional corpora lutea (CL) or regressing CL by two s.c. injections of 60 mg DHEA/kg body weight (DHEA group), 24 h apart on days 3 and 4 after ovulation, followed by decapitation on day 5 (functional CL) or on day 7 and 8, followed by decapitation on day 9 (regressing CL). |
|
Dosage form |
s.c., 60 mg/kg |
|
Applications |
In mice with functional CL (day 5), the hyperandrogenization with dehydroepiandrosterone (DHEA) decreased both serum P and estradiol (E2) levels when compared to controls |
|
References: |
|
| Cas No. | 53-43-0 | SDF | |
| Synonyms | Androstenolone, trans-Dehydroandrosterone, DHEA, Diandrone, NSC 9896, Prasterone, Psicosterone | ||
| Chemical Name | (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one | ||
| Canonical SMILES | CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C | ||
| Formula | C19H28O2 | M.Wt | 288.42 |
| Solubility | ≥ 13.7 mg/mL in DMSO, ≥ 58.6 mg/mL in ETOH | Storage | Store at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4672 mL | 17.3358 mL | 34.6717 mL |
| 5 mM | 693.4 μL | 3.4672 mL | 6.9343 mL |
| 10 mM | 346.7 μL | 1.7336 mL | 3.4672 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)